High-Quality Dexmedetomidine Hydrochloride (API) Meeting CP & EP Standards

Liposomes as Drug Delivery Vehicles

BioIVT Launches GMP-grade VivoSTART Leukopaks for Cell and Gene Therapy Manufacturing

VivoSTART GMP-grade leukopaks complement BioIVT’s GMP-grade human AB serum, providing a complete solution for advanced therapy development.

Integrated DNA Technologies Expands Customization Options for Alt-R™ Custom CRISPR gRNA Libraries for Drug Discovery

Inizio Biotech makes key leadership appointment to meet demand from emerging biotech

Anti-inflammatory drug candidate DMXD-011 shows efficacy in ex-vivo human studies

TFDA Grants CTL Amedica License to Market MATISSE™ ACIF Cage System

The Taiwan Food and Drug Administration has granted CTL Amedica Corporation a license to market the MATISSE Anterior Cervical Interbody Fusion (ACIF) Cage System.

Clinion - Platinum Sponsor for ISCR 3rd Autumn Conference 2022

BrightInsight Selects Lyniate to Enhance Interoperability Strategic Engagement Will Improve Information Exchange for Regulated Digital Health Solutions Built on the BrightInsight® Platform

Graphene Modification Helps to Unlock New Potentials

Accelerated Shelf-Life Testing to Assess Drug Stability

Four Most Commonly Used Surfactants You Should Know

Bora expands its CDMO capabilities as it makes landmark acquisition of TWi Pharmaceuticals

BioIVT Acquires XenoTech, a Leading Provider of Products and Services for Preclinical Testing of New Drug Candidates

XenoTech specializes in providing ADME-Tox products and research services, in particular drug metabolism and pharmacokinetics (DMPK) and drug-drug interaction (DDI) studies.

Molecular Devices and HeartBeat.bio announce collaboration to automate and scale cardiac organoids for high-throughput screening in drug discovery

Molecular Devices and HeartBeat.bio AG have entered into a co-development agreement to commercialize a first-of-its-kind automated offering that will enable researchers to reliably scale production of Cardioids and advance cardiac drug discovery.

BOC Sciences Outlines Its Contribution of Peptides to Cardiovascular Research

BOC Sciences' monthly report released in August showed that its peptide products had vastly facilitated the R&D of cardiovascular therapies.

Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022

DNAnexus Selected as Platform Provider of the Trusted Research Environment for UK’s Largest Health Research Program

DNAnexus awarded a 3-year contract by Our Future Health to provide a scalable, cloud-based trusted research environment for the large-scale population research program that aims to recruit up to 5 million volunteers. Approved researchers from the global life sciences, healthcare, and academic communities will be able to use the DNAnexus platform to securely explore and analyze the de-identified data.

BOC Sciences August Promotion: Comprehensive Labeled Peptides with Stable Quality

As a pioneer in stable isotopic labeling chemistry, BOC Sciences develops a large variety of SIL compounds. Its promotion of labeled peptides, the increasingly used materials for convenient detection in research, is on the boil in August.

BOC Sciences 2022 Free Webinar: Viral RNA Modifications and Implications for Novel Therapeutics

BOC Sciences grandly announced the schedule of a free webinar on September 19th, 2022, at 11:00 EDT, which is a laudable event centering on the hot spot of RNA research during the pandemic.